



NRG-GY036 Trial for Ovarian Cancer Month:

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

[Click here to Listen](#)

Episode Description: For the 2026 Ovarian Cancer Month & Gynecologic Cancer Month, we discuss the currently enrolling NRG-GY036 clinical trial comparing 1 vs. 2 years of maintenance olaparib (with or without bevacizumab) for patients with advanced ovarian cancer with Dr. Liu.



All episodes of The NRG Oncology Podcast can be found on Spotify, Apple Music, YouTube, & Amazon or you can stream them directly from our website at

www.NRGOncology.org/Podcast